BeiGene, Ltd.

NASDAQ

Market Cap.

1.97B

Avg. Volume

452.97K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about BeiGene, Ltd.

BeiGene, Ltd. News

BeiGene, Ltd. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareMedical - Pharmaceuticals
beigene.com

About BeiGene, Ltd.

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeiGene, Ltd. Earnings & Revenue

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

BeiGene, Ltd. Financials

Table Compare

Compare ONC metrics with:

   

Earnings & Growth

ONC

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ONC

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ONC

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ONC

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

BeiGene, Ltd. Income

BeiGene, Ltd. Balance Sheet

BeiGene, Ltd. Cash Flow

BeiGene, Ltd. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

BeiGene, Ltd. Executives

NameRole
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
Mr. John V. OylerCo-Founder, Executive Chairman & Chief Executive Officer
Mr. Aaron RosenbergChief Financial Officer
Dr. Xiaobin Wu Ph.D.President, Chief Operating Officer & GM of China
Mr. Wang Lai Ph.D.Global Head of R&D
NameRoleGenderDate of BirthPay
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder19634.25M
Mr. John V. OylerCo-Founder, Executive Chairman & Chief Executive OfficerMale19682.84M
Mr. Aaron RosenbergChief Financial OfficerMale19771.93M
Dr. Xiaobin Wu Ph.D.President, Chief Operating Officer & GM of China19631.84M
Mr. Wang Lai Ph.D.Global Head of R&DMale19781.2M

BeiGene, Ltd. Insider Trades

Date21 May
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionAcquired
TypeA-Award
Shares21970
Date21 May
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionAcquired
TypeA-Award
Shares21970
Date21 May
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionAcquired
TypeA-Award
Shares45500
Date28 Feb
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionDisposed
TypeS-Sale
Shares60851
Date28 Feb
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionDisposed
TypeS-Sale
Shares671976
DateNameRoleTransactionTypeShares
21 MayBAKER BROS. ADVISORS LPDirectorAcquiredA-Award21970
21 MayBAKER BROS. ADVISORS LPDirectorAcquiredA-Award21970
21 MayBAKER BROS. ADVISORS LPDirectorAcquiredA-Award45500
28 FebBAKER BROS. ADVISORS LPDirectorDisposedS-Sale60851
28 FebBAKER BROS. ADVISORS LPDirectorDisposedS-Sale671976

Discover More

Streamlined Academy

BeiGene, Ltd.

NASDAQ

Market Cap.

1.97B

Avg. Volume

452.97K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

BeiGene, Ltd. News

BeiGene, Ltd. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

BeiGene, Ltd. Earnings & Revenue

BeiGene, Ltd. Income

BeiGene, Ltd. Balance Sheet

BeiGene, Ltd. Cash Flow

BeiGene, Ltd. Financials Over Time

BeiGene, Ltd. Executives

NameRole
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
Mr. John V. OylerCo-Founder, Executive Chairman & Chief Executive Officer
Mr. Aaron RosenbergChief Financial Officer
Dr. Xiaobin Wu Ph.D.President, Chief Operating Officer & GM of China
Mr. Wang Lai Ph.D.Global Head of R&D
NameRoleGenderDate of BirthPay
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder19634.25M
Mr. John V. OylerCo-Founder, Executive Chairman & Chief Executive OfficerMale19682.84M
Mr. Aaron RosenbergChief Financial OfficerMale19771.93M
Dr. Xiaobin Wu Ph.D.President, Chief Operating Officer & GM of China19631.84M
Mr. Wang Lai Ph.D.Global Head of R&DMale19781.2M

BeiGene, Ltd. Insider Trades

Date21 May
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionAcquired
TypeA-Award
Shares21970
Date21 May
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionAcquired
TypeA-Award
Shares21970
Date21 May
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionAcquired
TypeA-Award
Shares45500
Date28 Feb
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionDisposed
TypeS-Sale
Shares60851
Date28 Feb
NameBAKER BROS. ADVISORS LP
RoleDirector
TransactionDisposed
TypeS-Sale
Shares671976
DateNameRoleTransactionTypeShares
21 MayBAKER BROS. ADVISORS LPDirectorAcquiredA-Award21970
21 MayBAKER BROS. ADVISORS LPDirectorAcquiredA-Award21970
21 MayBAKER BROS. ADVISORS LPDirectorAcquiredA-Award45500
28 FebBAKER BROS. ADVISORS LPDirectorDisposedS-Sale60851
28 FebBAKER BROS. ADVISORS LPDirectorDisposedS-Sale671976

Streamlined Academy

Website screenshot
HealthcareMedical - Pharmaceuticals
beigene.com

About BeiGene, Ltd.

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about BeiGene, Ltd.

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

BeiGene, Ltd. Financials

Table Compare

Compare ONC metrics with:

   

Earnings & Growth

ONC

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ONC

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ONC

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ONC

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

The Secret to Analyzing Winning Stocks (Step-by-Step Examples Inside)